Welcome to our dedicated page for Procept Biorobotics news (Ticker: PRCT), a resource for investors and traders seeking the latest updates and insights on Procept Biorobotics stock.
PROCEPT BioRobotics Corporation (Nasdaq: PRCT) is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. News about PROCEPT BioRobotics frequently centers on its AQUABEAM and HYDROS Robotic Systems, which deliver Aquablation therapy for benign prostatic hyperplasia (BPH) and are being evaluated in clinical studies for localized prostate cancer.
Investors and clinicians following PRCT news can expect regular updates on quarterly financial results, revenue guidance, and operating metrics such as U.S. system placements, handpiece and consumable revenue, and international performance. The company issues detailed earnings press releases and hosts conference calls and webcasts to discuss its results and outlook.
Company news also covers clinical and regulatory milestones. Examples include progress in the WATER IV Prostate Cancer Trial, which compares Aquablation therapy with radical prostatectomy, and developments related to reimbursement, such as the assignment of a Category I CPT code for Aquablation therapy in the Medicare Proposed Physician Fee Schedule. These items provide insight into how the therapy is being integrated into clinical practice and payment systems.
Additional PRCT headlines highlight participation in healthcare and investor conferences, executive leadership updates, and commentary on the growing body of peer-reviewed publications supporting Aquablation therapy. For anyone tracking the evolution of robotic urology treatments, the PROCEPT BioRobotics news feed offers a centralized view of financial performance, clinical research, reimbursement changes, and corporate events related to Aquablation therapy and the company’s robotic platforms.
PROCEPT BioRobotics (Nasdaq: PRCT) hosted its 2026 Investor Day outlining a multi-year plan to drive leadership in BPH with Aquablation therapy. Management projects 2026 revenue growth of 27%–33%, 2026 procedure growth of 39%–48%, and 2026 gross margin of 65%, improving to 68%–70% in 2027.
The company expects positive adjusted EBITDA in Q4 2026 and a 2027 adjusted EBITDA gain of $25–30 million. WATER IV prostate cancer trial procedures are expected complete by mid-2026, and more than 125,000 patients have been treated to date.
PROCEPT BioRobotics (Nasdaq: PRCT) reported Q4 2025 revenue of $76.4M, full-year 2025 revenue of $308.1M (+37% YoY) and Q4 procedure volume of ~12,200 (Q4 handpieces ~9,400).
Q4 sold 65 systems, ending U.S. install base 718 systems (+42% YoY). Q4 gross margin 61%; net loss $29.8M. 2026 guidance: revenue $390–$410M, gross margin ~65%, adjusted EBITDA loss $30M–$17M.
PROCEPT BioRobotics (Nasdaq: PRCT) updated timing for its fourth quarter 2025 earnings release and Investor Day due to travel disruptions from inclement weather.
The Company will report Q4 2025 results after market close on Wednesday, February 25, 2026, with a conference call at 4:30 p.m. ET. The in-person Investor Day is rescheduled to Thursday, February 26, 2026, 8:00 a.m. ET at NASDAQ Headquarters in New York City. A live webcast and archived recordings will be available on the Investors section of the company website and replayed for at least 90 days.
PROCEPT BioRobotics (Nasdaq: PRCT) said members of management will present at two investor conferences in March 2026: a fireside chat at TD Cowen in Boston on March 2, 2026 at 11:40am ET and a fireside chat at Leerink in Miami on March 10, 2026 at 8:00am ET.
A live webcast and archived recordings will be available on the company Investors website and retained for at least 90 days after each event.
PROCEPT BioRobotics (Nasdaq: PRCT) will report fourth-quarter 2025 results after market close on Tuesday, February 24, 2026, followed by a conference call at 4:30 p.m. ET. The company will host an in-person Investor Day at NASDAQ Headquarters in New York City on Wednesday, February 25, 2026, beginning at 8:00 a.m. ET. Guests are encouraged to register in advance to secure a spot. A live webcast of both events will be available on the company’s Investors website and each webcast will be archived and available for replay for at least 90 days after the event.
PROCEPT BioRobotics (Nasdaq: PRCT) announced management will present at the 37th Annual Piper Sandler Healthcare Conference in New York City on Tuesday, December 2, 2025 at 8:30 a.m. ET.
A live webcast and archived recording will be available in the company’s Investors section at https://ir.procept-biorobotics.com, with replays accessible for at least 90 days after the event.
PROCEPT BioRobotics (Nasdaq: PRCT) reported third-quarter 2025 results with Q3 revenue of $83.3M, up 43% year‑over‑year, and U.S. handpiece and consumables revenue of $44.4M (+50% YoY). The U.S. installed base reached 653 systems after adding 58 systems in the quarter. Gross margin expanded to 65%. Net loss was $21.4M and adjusted EBITDA loss improved to $7.4M in Q3. Cash and equivalents totaled $297.3M as of September 30, 2025. The company reiterated 2025 revenue guidance of about $325.5M and issued 2026 revenue guidance of $410–$430M (growth 26%–32%).
PROCEPT BioRobotics (Nasdaq: PRCT) announced it will report third quarter 2025 financial results after market close on Tuesday, November 4, 2025.
Management will host a conference call the same day at 4:30 p.m. Eastern Time. Investors can listen via webcast or dial-in registration. Live and archived audio will be available in the company’s Investors section; each webcast will be replayable for at least 90 days.
Jupiter Endovascular (ISRG) closed an oversubscribed Series B financing that surpassed its $40 million target, led by Sonder Capital with participation from Senvest Management, LB Investment, and a new strategic corporate investor. Proceeds will fund completion of the SPIRARE II pivotal trial, commercialization preparation, and new TFX applications. The announcement follows an FDA 510(k) clearance last month for the Vertex Catheter with TFX and precedes presentation of first-in-human SPIRARE I results at TCT on October 26, 2025. SPIRARE II plans to enroll up to 145 patients at up to 25 U.S. and European sites.
PROCEPT BioRobotics (Nasdaq: PRCT) reported strong Q2 2025 financial results with total revenue of $79.2 million, up 48% year-over-year. The company's U.S. revenue grew 46% to $69.6 million, driven by system sales and increased handpiece revenue. International revenue surged 69% to $9.6 million.
Key highlights include 51 new U.S. robotic system sales and an expanded U.S. install base of 595 systems. Gross margin improved to 65% from 59% year-over-year. The company increased its 2025 revenue guidance to $325.5 million, representing 45% growth. Additionally, PROCEPT announced the appointment of Larry Wood as CEO, effective September 2, 2025.